Types of acute phase reactants and their importance in vaccination (Review)

Khalil,Rafaat   H.; Al-Humadi,Nabil

doi:10.3892/br.2020.1276

Types of acute phase reactants and their importance in vaccination (Review)

Authors:
- Rafaat H. Khalil
- Nabil Al-Humadi
View Affiliations

Affiliations: Department of Biology, College of Science and Technology, Florida Agricultural and Mechanical University, Tallahassee, FL 32307, USA, Office of Vaccines, Food and Drug Administration, Center for Biologics Evaluation and Research, Silver Spring, MD 20993, USA
Published online on: February 11, 2020 https://doi.org/10.3892/br.2020.1276
Pages: 143-152
Copyright: © Khalil et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vaccines are considered to be one of the most cost‑effective life‑saving interventions in human history. The body's inflammatory response to vaccines has both desired effects (immune response), undesired effects [(acute phase reactions (APRs)] and trade‑offs. Trade‑offs are more potent immune responses which may be potentially difficult to separate from potent acute phase reactions. Thus, studying acute phase proteins (APPs) during vaccination may aid our understanding of APRs and homeostatic changes which can result from inflammatory responses. Depending on the severity of the response in humans, these reactions can be classified as major, moderate or minor. In this review, types of APPs and their importance in vaccination will be discussed.

View Figures

View References

1	Deans C and Wigmore SJ: Systemic inflammation, cachexia and prognosis in patients with cancer. Curr Opin Clin Nutr Metab Care. 8:265–269. 2005.PubMed/NCBI View Article : Google Scholar
2	Ridker PM: Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: Implications for longevity. Nutr Rev. 65 (Suppl):S253–S259. 2007.PubMed/NCBI View Article : Google Scholar
3	Cray C, Zaias J and Altman NH: Acute phase response in animals: A review. Comp Med. 59:517–526. 2009.PubMed/NCBI
4	Boosalis MG, Snowdon DA, Tully CL and Gross MD: Acute phase response and plasma carotenoid concentrations in older women: Findings from the nun study. Nutrition. 12:475–478. 1996.PubMed/NCBI View Article : Google Scholar
5	Mackiewicz A: Acute phase proteins and transformed cells. Int Rev Cytol. 170:225–300. 1997.PubMed/NCBI View Article : Google Scholar
6	Koj A: Termination of acute-phase response: Role of some cytokines and anti-inflammatory drugs. Gen Pharmacol. 31:9–18. 1998.PubMed/NCBI View Article : Google Scholar
7	Ceron JJ, Eckersall PD and Martynez-Subiela S: Acute phase proteins in dogs and cats: Current knowledge and future perspectives. Vet Clin Pathol. 34:85–99. 2005.PubMed/NCBI View Article : Google Scholar
8	Gómez-Laguna J, Salguero FJ, Pallarés FJ, Rodríguez-Gómez IM, Barranco I and Carrasco L: Acute phase proteins as biomarkers in animal health and welfare. In: Acute Phase Proteins As Early Non-Specific Biomarkers of Human and Veterinary Diseases. Veas F (ed). InTech, pp259-298, 2011.
9	Sharpe-Timms KL, Nabli H, Zimmer RL, Birt JA and Davis JW: Inflammatory cytokines differentially up-regulate human endometrial haptoglobin production in women with endometriosis. Hum Reprod. 25:1241–1250. 2010.PubMed/NCBI View Article : Google Scholar
10	Suk HJ, Ridker PM, Cook NR and Zee RY: Relation of polymorphism within the C-reactive protein gene and plasma CRP levels. Atherosclerosis. 178:139–145. 2005.PubMed/NCBI View Article : Google Scholar
11	Macleod CM and Avery OT: The occurrence during acute infections of a protein not normally present in the blood: II. Isolation and properties of the reactive protein. J Exp Med. 73:183–190. 1941.PubMed/NCBI View Article : Google Scholar
12	Ballou SP and Kushner I: C-reactive protein and the acute phase response. Adv Intern Med. 37:313–336. 1992.PubMed/NCBI
13	Anderson HC and McCarty M: The occurrence in the rabbit of an acute phase protein analogous to human C reactive protein. J Exp Med. 93:25–36. 1951.PubMed/NCBI View Article : Google Scholar
14	Mold C, Rodriguez W, Rodic-Polic B and Du Clos TW: C-reactive protein mediates protection from lipopolysaccharide through interactions with Fc gamma R. J Immunol. 169:7019–7025. 2002.PubMed/NCBI View Article : Google Scholar
15	Volanakis JE and Kaplan MH: Specificity of C-reactive protein for choline phosphate residues of pneumococcal C-polysaccharide. Proc Soc Exp Biol Med. 136:612–614. 1971.PubMed/NCBI View Article : Google Scholar
16	Gabay C and Kushner I: Acute-phase proteins and other systemic responses to inflammation. N Engl J Med. 340:448–454. 1999.PubMed/NCBI View Article : Google Scholar
17	Volanakis JE: Acute phase proteins in rheumatic disease. In: Arthritis and allied conditions: A textbook of rheumatology. Koopman WJ (ed). 13 edition. Williams & Wilkins, Baltimore, MD, pp505-514, 1997.
18	Rao AK, Chouhan V, Chen X, Sun L and Boden G: Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes. 48:1156–1161. 1999.PubMed/NCBI View Article : Google Scholar
19	Stegenga ME, van der Crabben SN, Levi M, de Vos AF, Tanck MW, Sauerwein HP and van der Poll T: Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes. 55:1807–1812. 2006.PubMed/NCBI View Article : Google Scholar
20	Pepys MB and Hirschfield GM: C-reactive protein: A critical update. J Clin Invest. 111:1805–1812. 2003.PubMed/NCBI View Article : Google Scholar
21	Falsey AR, Walsh EE, Francis CW, Looney RJ, Kolassa JE, Hall WJ and Abraham GN: Response of C-reactive protein and serum amyloid A to influenza A infection in older adults. J Infect Dis. 183:995–999. 2001.PubMed/NCBI View Article : Google Scholar
22	Woloshin S and Schwartz LM: Distribution of C-reactive protein values in the United States. N Engl J Med. 352:1611–1613. 2005.PubMed/NCBI View Article : Google Scholar
23	Yen-Watson B and Kushner I: Rabbit CRP response to endotoxin administration: Dose-response relationship and kinetics. Proc Soc Exp Biol Med. 146:1132–1136. 1974.PubMed/NCBI View Article : Google Scholar
24	Langlois MR and Delanghe JR: Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 42:1589–1600. 1996.PubMed/NCBI
25	Bowman BH and Kurosky A: Haptoglobin: The evolutionary product of duplication, unequal crossing over, and point mutation. Adv Hum Genet. 12:189–261, 453-184. 1982.PubMed/NCBI View Article : Google Scholar
26	Alayash AI: Redox biology of blood. Antioxid Redox Signal. 6:941–943. 2004.PubMed/NCBI View Article : Google Scholar
27	Eklund KK, Niemi K and Kovanen PT: Immune functions of serum amyloid A. Crit Rev Immunol. 32:335–348. 2012.PubMed/NCBI View Article : Google Scholar
28	Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT and Solomon SB: Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 115:3409–3417. 2005.PubMed/NCBI View Article : Google Scholar
29	Gilstad CW: Anaphylactic transfusion reactions. Curr Opin Hematol. 10:419–423. 2003.PubMed/NCBI View Article : Google Scholar
30	Larsen K, Macleod D, Nihlberg K, Gurcan E, Bjermer L, Marko-Varga G and Westergren-Thorsson G: Specific haptoglobin expression in bronchoalveolar lavage during differentiation of circulating fibroblast progenitor cells in mild asthma. J Proteome Res. 5:1479–1483. 2006.PubMed/NCBI View Article : Google Scholar
31	Shimada E, Tadokoro K, Watanabe Y, Ikeda K, Niihara H, Maeda I, Isa K, Moriya S, Ashida T, Mitsunaga S, et al: Anaphylactic transfusion reactions in haptoglobin-deficient patients with IgE and IgG haptoglobin antibodies. Transfusion. 42:766–773. 2002.PubMed/NCBI View Article : Google Scholar
32	Arredouani M, Matthijs P, Van Hoeyveld E, Kasran A, Baumann H, Ceuppens JL and Stevens E: Haptoglobin directly affects T cells and suppresses T helper cell type 2 cytokine release. Immunology. 108:144–151. 2003.PubMed/NCBI View Article : Google Scholar
33	Saeed SA, Ahmad N and Ahmed S: Dual inhibition of cyclooxygenase and lipoxygenase by human haptoglobin: Its polymorphism and relation to hemoglobin binding. Biochem Biophys Res Commun. 353:915–920. 2007.PubMed/NCBI View Article : Google Scholar
34	Pepys MB, Dash AC, Markham RE, Thomas HC, Williams BD and Petrie A: Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. Clin Exp Immunol. 32:119–124. 1978.PubMed/NCBI
35	Derebe MG, Zlatkov CM, Gattu S, Ruhn KA, Vaishnava S, Diehl GE, MacMillan JB, Williams NS and Hooper LV: Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife. 3(e03206)2014.PubMed/NCBI View Article : Google Scholar
36	Bottazzi B, Doni A, Garlanda C and Mantovani A: An integrated view of humoral innate immunity: Pentraxins as a paradigm. Annu Rev Immunol. 28:157–183. 2010.PubMed/NCBI View Article : Google Scholar
37	Hind CR, Collins PM, Renn D, Cook RB, Caspi D, Baltz ML and Pepys MB: Binding specificity of serum amyloid P component for the pyruvate acetal of galactose. J Exp Med. 159:1058–1069. 1984.PubMed/NCBI View Article : Google Scholar
38	Loveless RW, Floyd-O'Sullivan G, Raynes JG, Yuen CT and Feizi T: Human serum amyloid P is a multispecific adhesive protein whose ligands include 6-phosphorylated mannose and the 3-sulphated saccharides galactose, N-acetylgalactosamine and glucuronic acid. EMBO J. 11:813–819. 1992.PubMed/NCBI View Article : Google Scholar
39	Familian A, Zwart B, Huisman HG, Rensink I, Roem D, Hordijk PL, Aarden LA and Hack CE: Chromatin-independent binding of serum amyloid P component to apoptotic cells. J Immunol. 167:647–654. 2001.PubMed/NCBI View Article : Google Scholar
40	Husby G, Marhaug G, Dowton B, Sletten K and Sipe JD: Serum amyloid A (SAA): Biochemistry, genetics and the pathogenesis of AA amyloidosis. Int J Exu Clin Invest. 1:119–137. 1994. View Article : Google Scholar
41	Wang S, Murphy CL, Kestler D, Macy SD, Williams TK, Weiss DT and Solomon A: SAA4-related AA amyloidosis. In: XIth International Symposium on Amyloidosis. CRC Press, Boca Raton, FL, 2008.
42	Eriksen N and Benditt EP: Isolation and characterization of the amyloid-related apoprotein (SAA) from human high density lipoprotein. Proc Natl Acad Sci USA. 77:6860–6864. 1980.PubMed/NCBI View Article : Google Scholar
43	Levy JH, Szlam F, Tanaka KA and Sniecienski RM: Fibrinogen and hemostasis: A primary hemostatic target for the management of acquired bleeding. Anesth Analg. 114:261–274. 2012.PubMed/NCBI View Article : Google Scholar
44	Jennewein C, Tran N, Paulus P, Ellinghaus P, Eble JA and Zacharowski K: Novel aspects of fibrin(ogen) fragments during inflammation. Mol Med. 17:568–573. 2011.PubMed/NCBI View Article : Google Scholar
45	Mosesson MW: Fibrinogen and fibrin structure and functions. J Thromb Haemost. 3:1894–1904. 2005.PubMed/NCBI View Article : Google Scholar
46	Meyer MA, Ostrowski SR, Windelov NA and Johansson PI: Fibrinogen concentrates for bleeding trauma patients: What is the evidence? Vox Sang. 101:185–190. 2011.PubMed/NCBI View Article : Google Scholar
47	Furie B and Furie BC: The molecular basis of blood coagulation. Cell. 53:505–518. 1988.PubMed/NCBI View Article : Google Scholar
48	Colvin RB, Johnson RA, Mihm MC Jr and Dvorak HF: Role of the clotting system in cell-mediated hypersensitivity. I. Fibrin deposition in delayed skin reactions in man. J Exp Med. 138:686–698. 1973.PubMed/NCBI View Article : Google Scholar
49	Labarrere CA, Nelson DR and Faulk WP: Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med. 105:207–213. 1998.PubMed/NCBI View Article : Google Scholar
50	Ryden L and Eaker D: Identification of the thiol groups in human ceruloplasmin. Eur J Biochem. 132:241–247. 1983.PubMed/NCBI View Article : Google Scholar
51	Jamieson GA: Studies on Glycoproteins. I. The carbohydrate portion of human ceruloplasmin. J Biol Chem. 240:2019–2027. 1965.PubMed/NCBI
52	Harris ZL, Klomp LW and Gitlin JD: Aceruloplasminemia: An inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr. 67 (5 Suppl):972S–977S. 1998.PubMed/NCBI View Article : Google Scholar
53	Colombo S, Buclin T, Decosterd LA, Telenti A, Furrer H, Lee BL, Biollaz J and Eap CB: Swiss HIV Cohort Study: Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: Effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation. Clin Pharmacol Ther. 80:307–318. 2006.PubMed/NCBI View Article : Google Scholar
54	Osaki S, Johnson DA and Frieden E: The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem. 241:2746–2751. 1966.PubMed/NCBI
55	Osaki S, Johnson DA and Frieden E: The mobilization of iron from the perfused mammalian liver by a serum copper enzyme, ferroxidase I. J Biol Chem. 246:3018–3023. 1971.PubMed/NCBI
56	Attieh ZK, Mukhopadhyay CK, Seshadri V, Tripoulas NA and Fox PL: Ceruloplasmin ferroxidase activity stimulates cellular iron uptake by a trivalent cation-specific transport mechanism. J Biol Chem. 274:1116–1123. 1999.PubMed/NCBI View Article : Google Scholar
57	Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RT and Gitlin JD: Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci USA. 92:2539–2543. 1995.PubMed/NCBI View Article : Google Scholar
58	Lahey ME, Gubler CJ, Chase MS, Cartwright GE and Wintrobe MM: Studies on copper metabolism. II. Hematologic manifestations of copper deficiency in swine. Blood. 7:1053–1074. 1952.PubMed/NCBI
59	Hochepied T, Berger FG, Baumann H and Libert C: Alpha(1)-acid glycoprotein: An acute phase protein with inflammatory and immunomodulating properties. Cytokine Growth Factor Rev. 14:25–34. 2003.PubMed/NCBI View Article : Google Scholar
60	Giurgea N, Constantinescu MI, Stanciu R, Suciu S and Muresan A: Ceruloplasmin-acute-phase reactant or endogenous antioxidant? The case of cardiovascular disease. Med Sci Monit. 11:RA48–RA51. 2005.PubMed/NCBI
61	Gutteridge JM: Caeruloplasmin: A plasma protein, enzyme, and antioxidant. Ann Clin Biochem. 15:293–296. 1978.PubMed/NCBI View Article : Google Scholar
62	Mukhopadhyay CK, Ehrenwald E and Fox PL: Ceruloplasmin enhances smooth muscle cell- and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism. J Biol Chem. 271:14773–14778. 1996.PubMed/NCBI View Article : Google Scholar
63	Mukhopadhyay CK, Mazumder B, Lindley PF and Fox PL: Identification of the prooxidant site of human ceruloplasmin: A model for oxidative damage by copper bound to protein surfaces. Proc Natl Acad Sci USA. 94:11546–11551. 1997.PubMed/NCBI View Article : Google Scholar
64	Smolarczyk K, Gils A, Boncela J, Declerck PJ and Cierniewski CS: Function-stabilizing mechanism of plasminogen activator inhibitor type 1 induced upon binding to alpha1-acid glycoprotein. Biochemistry. 44:12384–12390. 2005.PubMed/NCBI View Article : Google Scholar
65	Geboes K, Ray MB, Rutgeerts P, Callea F, Desmet VJ and Vantrappen G: Morphological identification of alpha-I-antitrypsin in the human small intestine. Histopathology. 6:55–60. 1982.PubMed/NCBI View Article : Google Scholar
66	Kremer JM, Wilting J and Janssen LH: Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 40:1–47. 1988.PubMed/NCBI
67	Barraud B, Balavoine S, Feldmann G and Lardeux B: Effects of insulin, dexamethasone and cytokines on alpha 1-acid glycoprotein gene expression in primary cultures of normal rat hepatocytes. Inflammation. 20:191–202. 1996.PubMed/NCBI View Article : Google Scholar
68	Mejdoubi N, Henriques C, Bui E, Durand G, Lardeux B and Porquet D: Growth hormone inhibits rat liver alpha-1-acid glycoprotein gene expression in vivo and in vitro. Hepatology. 29:186–194. 1999.PubMed/NCBI View Article : Google Scholar
69	Costello MJ, Gewurz H and Siegel JN: Inhibition of neutrophil activation by alpha1-acid glycoprotein. Clin Exp Immunol. 55:465–472. 1984.PubMed/NCBI
70	Laine E, Couderc R, Roch-Arveiller M, Vasson MP, Giroud JP and Raichvarg D: Modulation of human polymorphonuclear neutrophil functions by alpha 1-acid glycoprotein. Inflammation. 14:1–9. 1990.PubMed/NCBI View Article : Google Scholar
71	Tilg H, Vannier E, Vachino G, Dinarello CA and Mier JW: Antiinflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med. 178:1629–1636. 1993.PubMed/NCBI View Article : Google Scholar
72	Samak R, Edelstein R and Israel L: Immunosuppressive effect of acute-phase reactant proteins in vitro and its relevance to cancer. Cancer Immunol Immunother. 13:38–43. 1982.PubMed/NCBI View Article : Google Scholar
73	Muchitsch EM, Teschner W, Linnau Y and Pichler L: In vivo effect of alpha 1-acid glycoprotein on experimentally enhanced capillary permeability in guinea-pig skin. Arch Int Pharmacodyn Ther. 331:313–321. 1996.PubMed/NCBI
74	Perlmutter DH, Kay RM, Cole FS, Rossing TH, Van Thiel D and Colten HR: The cellular defect in alpha 1-proteinase inhibitor (alpha 1-PI) deficiency is expressed in human monocytes and in Xenopus oocytes injected with human liver mRNA. Proc Natl Acad Sci USA. 82:6918–6921. 1985.PubMed/NCBI View Article : Google Scholar
75	Ray MB, Geboes K, Callea F and Desmet VJ: Alpha-1-antitrypsin immunoreactivity in gastric carcinoid. Histopathology. 6:289–297. 1982.PubMed/NCBI View Article : Google Scholar
76	Berman MB, Barber JC, Talamo RC and Langley CE: Corneal ulceration and the serum antiproteases. I. Alpha 1-antitrypsin. Invest Ophthalmol. 12:759–770. 1973.PubMed/NCBI
77	Chowanadisai W and Lonnerdal B: Alpha(1)-antitrypsin and antichymotrypsin in human milk: Origin, concentrations, and stability. Am J Clin Nutr. 76:828–833. 2002.PubMed/NCBI View Article : Google Scholar
78	Huang CM: Comparative proteomic analysis of human whole saliva. Arch Oral Biol. 49:951–962. 2004.PubMed/NCBI View Article : Google Scholar
79	Janciauskiene S, Toth E, Sahlin S and Eriksson S: Immunochemical and functional properties of biliary alpha-1-antitrypsin. Scand J Clin Lab Invest. 56:597–608. 1996.PubMed/NCBI View Article : Google Scholar
80	Poortmans J and Jeanloz RW: Quantitative immunological determination of 12 plasma proteins excreted in human urine collected before and after exercise. J Clin Invest. 47:386–393. 1968.PubMed/NCBI View Article : Google Scholar
81	Boskovic G and Twining SS: Retinol and retinaldehyde specifically increase alpha1-proteinase inhibitor in the human cornea. Biochem J. 322:751–756. 1997.PubMed/NCBI View Article : Google Scholar
82	Lonnerdal B and Iyer S: Lactoferrin: Molecular structure and biological function. Annu Rev Nutr. 15:93–110. 1995.PubMed/NCBI View Article : Google Scholar
83	Garcia-Montoya IA, Cendon TS, Arevalo-Gallegos S and Rascon-Cruz Q: Lactoferrin a multiple bioactive protein: An overview. Biochim Biophys Acta. 1820:226–236. 2012.PubMed/NCBI View Article : Google Scholar
84	Singh PK, Parsek MR, Greenberg EP and Welsh MJ: A component of innate immunity prevents bacterial biofilm development. Nature. 417:552–555. 2002.PubMed/NCBI View Article : Google Scholar
85	Vogel HJ: Lactoferrin, a bird's eye view. Biochem Cell Biol. 90:233–244. 2012.PubMed/NCBI View Article : Google Scholar
86	Guntupalli K, Dean N, Morris PE, Bandi V, Margolis B, Rivers E, Levy M, Lodato RF, Ismail PM, Reese A, et al: A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of talactoferrin in patients with severe sepsis. Crit Care Med. 41:706–716. 2013.PubMed/NCBI View Article : Google Scholar
87	Digumarti R, Wang Y, Raman G, Doval DC, Advani SH, Julka PK, Parikh PM, Patil S, Nag S, Madhavan J, et al: A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer. J Thorac Oncol. 6:1098–1103. 2011.PubMed/NCBI View Article : Google Scholar
88	Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, Bapna A, Sekhon JS, Patil S, Ismail PM, et al: Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol. 29:4129–4136. 2011.PubMed/NCBI View Article : Google Scholar
89	Almond RJ, Flanagan BF, Antonopoulos A, Haslam SM, Dell A, Kimber I and Dearman RJ: Differential immunogenicity and allergenicity of native and recombinant human lactoferrins: Role of glycosylation. Eur J Immunol. 43:170–181. 2013.PubMed/NCBI View Article : Google Scholar
90	Lonnerdal B, Jiang R and Du X: Bovine lactoferrin can be taken up by the human intestinal lactoferrin receptor and exert bioactivities. J Pediatr Gastroenterol Nutr. 53:606–614. 2011.PubMed/NCBI View Article : Google Scholar
91	Davidson LA and Lonnerdal B: Persistence of human milk proteins in the breast-fed infant. Acta Paediatr Scand. 76:733–740. 1987.PubMed/NCBI View Article : Google Scholar
92	Wynn JL and Levy O: Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol. 37:307–337. 2010.PubMed/NCBI View Article : Google Scholar
93	Lambert LA: Molecular evolution of the transferrin family and associated receptors. Biochim Biophys Acta. 1820:244–255. 2012.PubMed/NCBI View Article : Google Scholar
94	Peters T Jr: All about albumin. Biochemistry, Genetics and Medical Applications. Academic Press, Inc., San Diego, CA, 1996.
95	Fasano M, Fanali G, Leboffe L and Ascenzi P: Heme binding to albuminoid proteins is the result of recent evolution. IUBMB Life. 59:436–440. 2007.PubMed/NCBI View Article : Google Scholar
96	Aisen P: Transferrin receptor 1. Int J Biochem Cell Biol. 36:2137–2143. 2004.PubMed/NCBI View Article : Google Scholar
97	Evans TW: Review article: Albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther. 16 (Suppl 5):S6–S11. 2002.PubMed/NCBI View Article : Google Scholar
98	Mendez CM, McClain CJ and Marsano LS: Albumin therapy in clinical practice. Nutr Clin Pract. 20:314–320. 2005.PubMed/NCBI View Article : Google Scholar
99	Gupta D and Lis CG: Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutr J. 9(69)2010.PubMed/NCBI View Article : Google Scholar
100	Koga M and Kasayama S: Clinical impact of glycated albumin as another glycemic control marker. Endocr J. 57:751–762. 2010.PubMed/NCBI View Article : Google Scholar
101	Sbarouni E, Georgiadou P and Voudris V: Ischemia modified albumin changes-review and clinical implications. Clin Chem Lab Med. 49:177–184. 2011.PubMed/NCBI View Article : Google Scholar
102	Marth E and Kleinhappl B: Albumin is a necessary stabilizer of TBE-vaccine to avoid fever in children after vaccination. Vaccine. 20:532–537. 2001.PubMed/NCBI View Article : Google Scholar
103	Haynes GR, Navickis RJ and Wilkes MM: Albumin administration-what is the evidence of clinical benefit? A systematic review of randomized controlled trials. Eur J Anaesthesiol. 20:771–793. 2003.PubMed/NCBI View Article : Google Scholar
104	Alderson P, Bunn F, Lefebvre C, Li WP, Li L, Roberts I and Schierhout G: Albumin Reviewers: Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev. 2004(CD001208)2004.PubMed/NCBI View Article : Google Scholar
105	Idzerda RL, Huebers H, Finch CA and McKnight GS: Rat transferrin gene expression: Tissue-specific regulation by iron deficiency. Proc Natl Acad Sci USA. 83:3723–3727. 1986.PubMed/NCBI View Article : Google Scholar
106	Macedo MF and de Sousa M: Transferrin and the transferrin receptor: Of magic bullets and other concerns. Inflamm Allergy Drug Targets. 7:41–52. 2008.PubMed/NCBI View Article : Google Scholar
107	Ingenbleek Y and Young V: Transthyretin (prealbumin) in health and disease: Nutritional implications. Annu Rev Nutr. 14:495–533. 1994.PubMed/NCBI View Article : Google Scholar
108	Ballmer PE: Causes and mechanisms of hypoalbuminaemia. Clin Nutr. 20:271–273. 2001.PubMed/NCBI View Article : Google Scholar
109	Cynober L, Prugnaud O, Lioret N, Duchemin C, Saizy R and Giboudeau J: Serum transthyretin levels in patients with burn injury. Surgery. 109:640–644. 1991.PubMed/NCBI
110	Yang HT, Yim H, Cho YS, Kim D, Hur J, Kim JH, Lee JW, Lee YK, Lee J, Han SW and Chun W: Serum transthyretin level is associated with clinical severity rather than nutrition status in massively burned patients. JPEN J Parenter Enteral Nutr. 38:966–972. 2014.PubMed/NCBI View Article : Google Scholar
111	Le Bricon T, Guidet B, Coudray-Lucas C, Staikowsky F, Gabillet JM, Offenstadt G, Giboudeau J and Cynober L: Biochemical assessment of nutritional status in patients with chronic obstructive pulmonary disease and acute respiratory failure on admission to an intensive care unit. Clin Nutr. 13:98–104. 1994.PubMed/NCBI View Article : Google Scholar
112	Germano Borges de Oliveira Nascimento Freitas R, Negrao Nogueira RJ and Hessel G: Protein needs of Critically Ill patients receiving parenteral nutrition. Nutr Hosp. 32:250–255. 2015.PubMed/NCBI View Article : Google Scholar
113	Yu PJ, Cassiere HA, Dellis SL, Manetta F, Kohn N and Hartman AR: Impact of preoperative prealbumin on outcomes after cardiac surgery. JPEN J Parenter Enteral Nutr. 39:870–874. 2015.PubMed/NCBI View Article : Google Scholar
114	Alsemgeest SP, Kalsbeek HC, Wensing T, Koeman JP, van Ederen AM and Gruys E: Concentrations of serum amyloid-A (SAA) and haptoglobin (HP) as parameters of inflammatory diseases in cattle. Vet Q. 16:21–23. 1994.PubMed/NCBI View Article : Google Scholar
115	Mills PC, Auer DE, Kramer H, Barry D and Ng JC: Effects of inflammation-associated acute-phase response on hepatic and renal indices in the horse. Aust Vet J. 76:187–194. 1998.PubMed/NCBI View Article : Google Scholar
116	Mills PC, Ng JC and Auer DE: The effect of inflammation on the disposition of phenylbutazone in thoroughbred horses. J Vet Pharmacol Ther. 19:475–481. 1996.PubMed/NCBI View Article : Google Scholar
117	Mills PC, Ng JC and Auer DE: The effect of the acute-phase response on in vitro drug metabolism and plasma protein binding in the horse. Vet Res Commun. 21:361–368. 1997.PubMed/NCBI View Article : Google Scholar
118	Jacobsen S, Andersen PH, Toelboell T and Heegaard PM: Dose dependency and individual variability of the lipopolysaccharide-induced bovine acute phase protein response. J Dairy Sci. 87:3330–3339. 2004.PubMed/NCBI View Article : Google Scholar
119	Araujo LM, Ribeiro OG, Siqueira M, De Franco M, Starobinas N, Massa S, Cabrera WH, Mouton D, Seman M and Ibañez OM: Innate resistance to infection by intracellular bacterial pathogens differs in mice selected for maximal or minimal acute inflammatory response. Eur J Immunol. 28:2913–2920. 1998.PubMed/NCBI View Article : Google Scholar
120	Verschuur M, van der Beek MT, Tak HS, Visser LG and de Maat MP: Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagul Fibrinolysis. 15:399–404. 2004.PubMed/NCBI View Article : Google Scholar
121	Elsasser TH, Blum JW and Kahl S: Characterization of calves exhibiting a novel inheritable TNF-alpha hyperresponsiveness to endotoxin: Associations with increased pathophysiological complications. J Appl Physiol (1985). 98:2045–2055. 2005.PubMed/NCBI View Article : Google Scholar
122	Park HL, Shim SH, Lee EY, Cho W, Park S, Jeon HJ, Ahn SY, Kim H and Nam JH: Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. Hum Vaccin Immunother. 10:1181–1186. 2014.PubMed/NCBI View Article : Google Scholar
123	Frasca D, Ferracci F, Diaz A, Romero M, Lechner S and Blomberg BB: Obesity decreases B cell responses in young and elderly individuals. Obesity (Silver Spring). 24:615–625. 2016.PubMed/NCBI View Article : Google Scholar
124	Lisciandro JG and van den Biggelaar AH: Neonatal immune function and inflammatory illnesses in later life: Lessons to be learnt from the developing world? Clin Exp Allergy. 40:1719–1731. 2010.PubMed/NCBI View Article : Google Scholar
125	Eckersall PD, Lawson FP, Bence L, Waterston MM, Lang TL, Donachie W and Fontaine MC: Acute phase protein response in an experimental model of ovine caseous lymphadenitis. BMC Vet Res. 3(35)2007.PubMed/NCBI View Article : Google Scholar
126	EL-Deeb WM and El-Bahr SM: Selected biochemical indicators of equine rhabdomyolysis in Arabian horses: Acute phase proteins and trace elements. Equine Vet Sci. 34:484–488. 2014. View Article : Google Scholar
127	EL-Deeb WM, El-Moslemany AM and Salem MA: Cardiac troponin I and immune inflammatory response in horses with strangles. Equine Vet Sci. 51:18–23. 2017. View Article : Google Scholar
128	Jones SA: Directing transition from innate to acquired immunity: Defining a role for IL-6. J Immunol. 175:3463–3468. 2005.PubMed/NCBI View Article : Google Scholar
129	Chomarat P, Banchereau J, Davoust J and Palucka AK: IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 1:510–514. 2000.PubMed/NCBI View Article : Google Scholar
130	van der Beek MT, Visser LG and de Maat MP: Yellow fever vaccination as a model to study the response to stimulation of the inflammation system. Vascul Pharmacol. 39:117–121. 2002.PubMed/NCBI View Article : Google Scholar
131	Kurtz SL, Foreman O, Bosio CM, Anver MR and Elkins KL: Interleukin-6 is essential for primary resistance to Francisella tularensis live vaccine strain infection. Infect Immun. 81:585–597. 2013.PubMed/NCBI View Article : Google Scholar
132	Tsai MY, Hanson NQ, Straka RJ, Hoke TR, Ordovas JM, Peacock JM, Arends VL and Arnett DK: Effect of influenza vaccine on markers of inflammation and lipid profile. J Lab Clin Med. 145:323–327. 2005.PubMed/NCBI View Article : Google Scholar
133	Posthouwer D, Voorbij HA, Grobbee DE, Numans ME and van der Bom JG: Influenza and pneumococcal vaccination as a model to assess C-reactive protein response to mild inflammation. Vaccine. 23:362–365. 2004.PubMed/NCBI View Article : Google Scholar
134	Treanor JJ, Taylor DN, Tussey L, Hay C, Nolan C, Fitzgerald T, Liu G, Kavita U, Song L, Dark I and Shaw A: Safety and immunogenicity of a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125) in healthy young adults. Vaccine. 28:8268–8274. 2010.PubMed/NCBI View Article : Google Scholar
135	Njoroge L, Khayata M, Zacharias M and ElAmm C: Acute myocarditis following influenza vaccine in a heart transplant patient. J Cardiac Failure. 24 (Suppl):S45–S46. 2018. View Article : Google Scholar
136	Garcon N, Leroux-Roels G and Cheng W: Vaccine adjuvants. In: Understanding Modern Vaccines: Perspectives in Vaccinology: Elsevier, pp89-113, 2011.
137	Mutwiri G, Gerdts V, van Drunen Littel-van den Hurk S, Auray G, Eng N, Garlapati S, Babiuk LA and Potter A: Combination adjuvants: The next generation of adjuvants? Expert Rev Vaccines. 10:95–107. 2011.PubMed/NCBI View Article : Google Scholar
138	Singh M, Ugozzoli M, Kazzaz J, Chesko J, Soenawan E, Mannucci D, Titta F, Contorni M, Volpini G, Del Guidice G and O'Hagan DT: A preliminary evaluation of alternative adjuvants to alum using a range of established and new generation vaccine antigens. Vaccine. 24:1680–1686. 2006.PubMed/NCBI View Article : Google Scholar
139	Leroux-Roels G: Unmet needs in modern vaccinology: Adjuvants to improve the immune response. Vaccine. 28 (Suppl 3):C25–C36. 2010.PubMed/NCBI View Article : Google Scholar
140	Destexhe E, Prinsen MK, van Schöll I, Kuper CF, Garçon N, Veenstra S and Segal L: Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies. J Pharmacol Toxicol Methods. 68:367–373. 2013.PubMed/NCBI View Article : Google Scholar
141	El Yousfi M, Mercier S, Breuillé D, Denis P, Papet I, Mirand PP and Obled C: The inflammatory response to vaccination is altered in the elderly. Mech Ageing Dev. 126:874–881. 2005.PubMed/NCBI View Article : Google Scholar
142	Liuba P, Aburawi EH, Pesonen E, Andersson S, Truedsson L, Ylä-Herttuala S and Holmberg L: Residual adverse changes in arterial endothelial function and LDL oxidation after a mild systemic inflammation induced by influenza vaccination. Ann Med. 39:392–399. 2007.PubMed/NCBI View Article : Google Scholar
143	He R, Shepard LW, Chen J, Pan ZK and Ye RD: Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J Immunol. 177:4072–4079. 2006.PubMed/NCBI View Article : Google Scholar
144	Lu P, Liu J and Pang X: Pravastatin inhibits fibrinogen- and FDP-induced inflammatory response via reducing the production of IL-6, TNF-alpha and iNOS in vascular smooth muscle cells. Mol Med Rep. 12:6145–6151. 2015.PubMed/NCBI View Article : Google Scholar
145	Lazzaro M, Bettegazzi B, Barbariga M, Codazzi F, Zacchetti D and Alessio M: Ceruloplasmin potentiates nitric oxide synthase activity and cytokine secretion in activated microglia. J Neuroinflammation. 11(164)2014.PubMed/NCBI View Article : Google Scholar
146	Martinez Cordero E, Gonzalez MM, Aguilar LD, Orozco EH and Hernandez Pando R: Alpha-1-acid glycoprotein, its local production and immunopathological participation in experimental pulmonary tuberculosis. Tuberculosis (Edinb). 88:203–211. 2008.PubMed/NCBI View Article : Google Scholar
147	de Serres F and Blanco I: Role of alpha-1 antitrypsin in human health and disease. J Intern Med. 276:311–335. 2014.PubMed/NCBI View Article : Google Scholar
148	Haversen L, Ohlsson BG, Hahn-Zoric M, Hanson LA and Mattsby-Baltzer I: Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell Immunol. 220:83–95. 2002.PubMed/NCBI View Article : Google Scholar
149	Du Clos TW: Function of C-reactive protein. Ann Med. 32:274–278. 2000.PubMed/NCBI View Article : Google Scholar
150	Spadaro M, Montone M, Arigoni M, Cantarella D, Forni G, Pericle F, Pascolo S, Calogero RA and Cavallo F: Recombinant human lactoferrin induces human and mouse dendritic cell maturation via Toll-like receptors 2 and 4. FASEB J. 28:416–429. 2014.PubMed/NCBI View Article : Google Scholar
151	Feelders RA, Vreugdenhil G, Eggermont AM, Kuiper-Kramer PA, van Eijk HG and Swaak AJ: Regulation of iron metabolism in the acute-phase response: Interferon gamma and tumour necrosis factor alpha induce hypoferraemia, ferritin production and a decrease in circulating transferrin receptors in cancer patients. Eur J Clin Invest. 28:520–527. 1998.PubMed/NCBI View Article : Google Scholar
152	Bartalena L, Farsetti A, Flink IL and Robbins J: Effects of interleukin-6 on the expression of thyroid hormone-binding protein genes in cultured human hepatoblastoma-derived (Hep G2) cells. Mol Endocrinol. 6:935–942. 1992.PubMed/NCBI View Article : Google Scholar
153	Louagie H, Delanghe J, Desombere I, De Buyzere M, Hauser P and Leroux-Roels G: Haptoglobin polymorphism and the immune response after hepatitis B vaccination. Vaccine. 11:1188–1190. 1993.PubMed/NCBI View Article : Google Scholar
154	Borthwick NJ, Lane T, Moyo N, Crook A, Shim JM, Baines I, Wee EG, Hawkins PN, Gillmore JD, Hanke T and Pepys MB: Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1. PLoS One. 13(e0197299)2018.PubMed/NCBI View Article : Google Scholar
155	Creech CB, Frenck RW Jr, Sheldon EA, Seiden DJ, Kankam MK, Zito ET, Girgenti D, Severs JM, Immermann FW, McNeil LK, et al: Safety, tolerability, and immunogenicity of a single dose 4-antigen or 3-antigen Staphylococcus aureus vaccine in healthy older adults: Results of a randomised trial. Vaccine. 35:385–394. 2017.PubMed/NCBI View Article : Google Scholar
156	Blom M, Prag JB and Norredam K: Alpha 1-Acid glycoprotein, alpha 1-antitrypsin, and ceruloplasmin in human intestinal helminthiases. Am J Trop Med Hyg. 28:76–83. 1979.PubMed/NCBI View Article : Google Scholar
157	Naylor C, Lu M, Haque R, Mondal D, Buonomo E, Nayak U, Mychaleckyj JC, Kirkpatrick B, Colgate R, Carmolli M, et al: Environmental enteropathy, oral vaccine failure and growth faltering in infants in bangladesh. EBioMedicine. 2:1759–1766. 2015.PubMed/NCBI View Article : Google Scholar
158	Hwang SA, Kruzel ML and Actor JK: Lactoferrin augments BCG vaccine efficacy to generate T helper response and subsequent protection against challenge with virulent Mycobacterium tuberculosis. Int Immunopharmacol. 5:591–599. 2005.PubMed/NCBI View Article : Google Scholar
159	Carty CL, Heagerty P, Nakayama K, McClung EC, Lewis J, Lum D, Boespflug E, McCloud-Gehring C, Soleimani BR, Ranchalis J, et al: Inflammatory response after influenza vaccination in men with and without carotid artery disease. Arterioscler Thromb Vasc Biol. 26:2738–2744. 2006.PubMed/NCBI View Article : Google Scholar
160	Patel C and Shah HH: Membranous nephropathy and severe acute kidney injury following influenza vaccination. Saudi J Kidney Dis Transpl. 26:1289–1293. 2015.PubMed/NCBI View Article : Google Scholar
161	Bos MP, Poolman J, Stork M, Tommassen JPM and Weynants V: Vaccine comprising protein NMB0964 from Neisseria meningitidis. US Patent 9,259,461. Filed March 6, 2009; issued August 4, 2011.